1. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
- Author
-
de Vries-Huizing DMV, Cheung ZJ, Hendrikx JJMA, Donswijk ML, and Versleijen MWJ
- Subjects
- Female, Humans, Aged, Radiopharmaceuticals, Octreotide adverse effects, Radioisotopes, Receptors, Peptide, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors radiotherapy, Organometallic Compounds adverse effects, Lutetium, Radionuclide Imaging, Positron-Emission Tomography
- Abstract
Abstract: Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF